The supply of plasma-derived medicinal products in the future of Europe

Second edition

23-24 April 2024
Rome, Italy

CENTRO NAZIONALE SANGUE

PLASMA ITALIA
italiaplasma.it

with the patronage of
Ministero della Salute

Recommendations on plasma collection and PDMPs management

Vincenzo De Angelis

National Blood Centre, Italy

Disclosure

I hereby declare that I have neither financial nor nonfinancial relationships related to any of the products or services described, reviewed, evaluated or compared in this presentation.

SUPPLY

Co-funded by the European Union

Work Package 4

National and EU infrastructures / policy / legal framework for plasma collection and PDMPs supply

- **Deliverable Report D4.6:**

Recommendations on plasma collection and PDMPs management

Sources

The set of recommendations will contribute to the SUPPLY future actions and benefits and summarises the information and conclusions included in key SUPPLY project surveys and reports including, *inter alia*:

D3.3 Report on the results of the “characterisation of the waste of recovered plasma and missed opportunities for plasmapheresis in European Union”;

D3.6 Recommendations on plasma donation quality;

D4.2 Analysis report: policies and/or legal frameworks on plasma collection and PDMPs management;

D4.4 Position Paper on PDMPs distribution;

D4.5 Assessment report on Plasma and PDMPs economics and tenders;

D6.1 Report on the results of: “A comparative analysis on the current use of immunoglobulins in individual countries: A clinical programme”;

Specific interviews with chosen EU and non-EU countries;

Addressing medicine shortages in the EU.

Legal provisions to consider / define plasma as a strategic resource.

- Only a minority of Member States (MS) has implemented a legislative framework aiming at promoting in an active way, the collection and the use of domestic plasma for the production of PDMPs;
- the majority of the MS did not take into due consideration the necessity of designing defined legal frameworks to consider domestic plasma as a strategic resource as to make their supply of PDMPs more independent from the market;
- this particular attention to PDMPs in the legislative work of the EU on this matter should remain, wherein the plasma resource can be recognised as strongly linked to the security of the supply chain of these medicines.

It is now necessary to recommend the adoption of a common legislative framework in the EU in terms of principles aimed at defining plasma as a strategic resource for the European citizens.

Legal provisions favouring cooperation among different systems and models.

- Public non-profit and private for-profit organisations play a role in collecting blood and plasma, both for transfusion and for manufacturing into PDMPs.
- Efforts must be made to avoid both competition between the operational models used, and competition for donors between the sectors in the collection of plasma for fractionation.

Cooperation between the public non-profit and private for-profit sectors should be facilitated and enabled by means of appropriate and specific legislative interventions aimed at securing the contribution of both sectors to the fundamental goal of meeting national (or even European) demand for PDMPs in a sustainable and resilient way.

Legal provisions favouring cooperation among MS.

- For-profit companies collect plasma in various European and non-European countries which is then fractionated after pooling only country by country, provided that the relevant collection centres are listed in the proprietary Plasma Master file (PMF).
- This is true also if plasma is collected by public facilities in the EU and then sold to both for-profit or non-for-profit organisations, which list the centres into their PMF as well.
- As a consequence, an EU MS collecting small volumes of plasma can sell the starting material to a fractionator only if the company is interested in including the collection facilities in its PMF. If this is not the case, this amount of plasma is wasted.

In order to share a common approach on the fractionation of domestic plasma and the production and the return of critical PDMPs, **EU should support and facilitate all MS in creating legal environments that both eliminate any barrier against the pooling of plasma from different MS and promote the agreements among two or more MS** (e.g., common toll manufacturing agreements or common tenders for selling plasma).

Legal provisions for the priority use of products coming from fractionation of domestic plasma

- Within MS national health systems, patients should have equitable access to safe and high-quality blood products and medicines derived from voluntary blood and plasma donations in the EU.
- Products derived from the fractionation of EU plasma should be primarily intended to meet the clinical needs of EU citizens.

The collection of EU plasma should be supported by adequate legal provisions, including recommendations for such at national level, to guarantee that plasma collected inside the EU gives origin to products which are made available for the therapeutic benefit of EU patients in the first instance.

EU plans supporting the increase and improvement of plasma collection

- True Strategic Independence of plasma and PDMPs in the EU will have been reached when an equal or larger volume of plasma is collected (source and/or recovered plasma) in the EU than is required to meet the maximum estimated plasma-related requirements of EU citizens.

In order to support national and EU efforts to achieve strategic independence from non-EU sources, **EU should launch and fund programmes aimed at increasing the quantity and quality of plasma collected by public and not-for profit Blood Establishments throughout the EU** and ultimately strengthening the resilience of plasma collection, also during emergency situations.

Thank you